TEL
AVIV, Israel, March 5,
2024 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
developing innovative therapeutics for fibro-inflammatory diseases
with high unmet need, today announced that CEO Dr.
Adi Mor will deliver a corporate
presentation and participate in investor meetings at the Leerink
Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida. Dr. Mor's presentation
will be webcast live and will be available at the investor
relations section of the Chemomab website for 90 days.
Leerink Partners Global BioPharma Conference
Date:
|
March 12,
2024
|
Time:
|
10:40am ET
|
Venue:
|
Fontainebleau
Hotel
|
Format:
|
Live presentation and
webcast
|
Webcast Link:
|
https://wsw.com/webcast/leerink33/cmmb/2189648
|
Information:
|
LeerinkEvents@Leerink.com
|
|
|
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab's CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready. For more information about
Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-leerink-global-biopharma-conference-302079499.html
SOURCE Chemomab Therapeutics Ltd